Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Irinotecan + VLX600|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 8||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|VLX600||VLX-600|VLX 600||VLX600 is a small molecule drug that inhibits mitochondrial oxidative phosphorylation, which impairs mitochondrial function and induces autophagy, potentially increasing cell death, and inhibiting proliferation, and tumor growth (PMID: 24548894, PMID: 30460505).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colon carcinoma||not applicable||Irinotecan + VLX600||Preclinical - Cell line xenograft||Actionable||In a preclinical study, VLX600 combined with Camptosar (irinotecan) synergistically inhibited viability of colon carcinoma cells in culture, and inhibited tumor growth in an orthotopic cell line xenograft model (PMID: 24548894).||24548894|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|